Oral multikinase inhibitor (e.g. Sorafenib, sunitinib) of the VEGF, PDGFR of downstream intracellular serine/threonine, is used with success in HCC therapy [17, 54]. The gene discussed is PDGFRB; the disease is hepatocellular carcinoma.